Edwards Lifesciences surpassed the S&P 500’s gains
As of September 28, Edwards Lifesciences (EW) has registered a rise of ~52.5% YTD (year-to-date). In the same period, the S&P 500 has risen ~9.2%.
So far, Edwards Lifesciences’ massive bull run has surpassed the market’s returns in 2018. In the last 12 months, Edwards Lifesciences stock has risen ~57%, which is more than three times the S&P 500’s return of ~16.4% during the same period.
Edwards Lifesciences stock is less volatile than the market, as reflected by its beta of 0.57 on September 28. A beta lower than one suggests that a stock is less volatile than the market, while a beta higher than one suggests more volatile stock compared to the market.
Industry and peer comparison
As of September 28, Edwards Lifesciences’ peers Medtronic (MDT), Abbott Laboratories (ABT), and Boston Scientific (BSX) generated returns of 25.7%, 40%, and 33%, respectively, over the last 12 months. The YTD returns of these stocks stand at 21%, 28%, and 55%, respectively.
The Health Care Select Sector SPDR ETF (XLV) and the iShares US Medical Devices ETF (IHI) have risen ~14.7% and ~30.4%, respectively, YTD. The data show that Edwards Lifesciences has mainly surpassed the stock price gains of the US healthcare sector and the US medical device industry in 2018.